Cybrexa Therapeutics to Present at BIO Digital and Sachs 6th Annual Digital Immuno-Oncology Innovation Forum
May 07, 2020 11:27 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics宣布医学博士Arthur DeCillis将担任代理首席医疗官，从而支持将CBX-12投入临床
March 31, 2020 09:16 ET
|
Cybrexa Therapeutics
康涅狄格州纽黑文, March 31, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家专注于肿瘤学的生物技术公司，通过其alphalex™肿瘤靶向平台开发全新治疗方法。该公司今天宣布，医学博士Arthur DeCillis已加入公司，担任代理首席医疗官。DeCillis博士将负责开发Cybrexa的领先计划CBX-12...
Cybrexa Therapeutics Announces Arthur DeCillis, MD as Acting Chief Medical Officer to Support CBX-12’s Entry into the Clinic
March 31, 2020 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
January 09, 2020 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
December 09, 2019 08:30 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
Cybrexa Therapeutics Announces Appointment of Biotech Industry Leader John Houston to Board of Directors
September 03, 2019 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today...
Cybrexa Therapeutics Receives SBIR Grant to Support Development of Lead Candidate CBX-11 in Combination with Chemotherapy Agents
July 02, 2019 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., July 02, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
Cybrexa Therapeutics Closes $13.4M in Series B1 Funding Round
June 20, 2019 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy
May 15, 2019 17:01 ET
|
Cybrexa Therapeutics
Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
Cybrexa Therapeutics to Present at the 2019 BIO International Convention
May 08, 2019 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...